CANNABINOID THERAPEUTICS

OVERVIEW

Although AXIM is transitioning its focus from a cannabinoid biotech to a cancer biotech company there is still a crossover and a large market opportunity. That is because cannabinoids are showing to exert various palliative effects in cancer patients and cannabinoids are proving to inhibit the growth of different types of tumor cells, in laboratory animals. Additionally, drug cocktails are a promising strategy for diseases such as cancer, because cocktails can be more effective than individual drugs and can overcome problems of drug resistance. A recent study showed that mice treated with both CBD oil and chemotherapy survived almost 3x longer than chemotherapy alone.

Other studies in vitro and in vivo focusing on pancreatic cancer found that cannabinoids can help slow tumor growth, reduce tumor invasion, and induce tumor cell death. A 2019 study indicated that CBD could provoke cell death and make glioblastoma cells more sensitive to radiation, but with no effect on healthy cells. A study in experimental models of colon cancer in vivo suggests that CBD may inhibit the spread of colorectal cancer cells. Other research demonstrated the efficacy of CBD in pre-clinical models of metastatic breast cancer. The study found that CBD significantly reduced breast cancer cell proliferation and invasion.

BACKGROUND

CANNABINOID WATER-SOLUBILITY

Cannabinoids are lipophilic molecules (i.e., oil-based compounds that are not soluble in water). This means that when you place extracted hemp oils into water, they float. Cannabionoids in their natural lipophilic state do not mix with water and will not dissolve in the water. This has always been the problem for oil-based compounds—because the human body is 60% water, they have difficulty dissolving, and more importantly, absorbing these molecules.

BACKGROUND

CANNABINOID 
WATER-SOLUBILITY

Cannabinoids are lipophilic molecules (i.e., oil-based compounds that are not soluble in water). This means that when you place extracted hemp oils into water, they float. Cannabionoids in their natural lipophilic state do not mix with water and will not dissolve in the water. This has always been the problem for oil-based compounds—because the human body is 60% water, they have difficulty dissolving, and more importantly, absorbing these molecules.

AXIM SOLUTION

POLYFUNTIONAL CANNABINOIDS

AXIM has leveraged its long-term experience in cannabinoid therapeutics, paired it with the molecular research conducted by recently acquired Sapphire Biotech, to develop a significantly more water soluble cannabinoid molecule.

AXIM SOLUTION

POLYFUNTIONAL 
CANNABINOIDS

AXIM has leveraged its long-term experience in cannabinoid therapeutics, paired it with the molecular research conducted by recently acquired Sapphire Biotech, to develop a significantly more water soluble cannabinoid molecule.

clinical development

STAGE ONE

The biological activity of the resulting compounds will be tested against native (unconjugated) CBD, CBG, CBDA and CBGA in functional binding, antibacterial/antifungal, and cancer proliferation assays